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Abstract: 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine) is a psychoactive substance, sold primarily 
over the Internet as a 'research chemical' or 'plant food'. Although details for the synthesis of this 
tryptamine have been available since 2004, its use as a hallucinogenic drug has been reported only 
occasionally in on-line user fora. It is controlled in only a few countries world-wide. There is little 
scientifically-based literature on the pharmacological, physiological, psychopharmacological, 
toxicological and epidemiological characteristics of 5-MeO-DALT. Here we review what is known about 
these aspects. We also report what we believe to be the first death involving the use of this substance. 
The case involved a man in his mid-20s who died in mid-2010. The coroner concluded that the 
deceased "died from injuries sustained after being hit by a lorry whilst under the influence of 5-MeO-
DALT". It is critical that any other cases, including non-fatal instances, are documented so that a 
scientific evidence-base can be established for this drug. 
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No ethical approval was required as the subject was deceased. 
 
 
Ethical Statement
Highlights  
 
 5-MeO-DALT is a psychoactive substance, sold mainly on Internet as a 
‘research chemical’  
 
 Use as a hallucinogenic is reported occasionally in on-line user fora; it can 
affect risk assessment 
 
 Scant scientific literature on physical effects, psychopharmacology, toxicology 
 
 Victim died from injuries sustained when hit by a vehicle whilst under its 
influence 
 
 Any other (non-) fatal cases need documenting to establish scientific 
evidence-base  
 
*Highlights (for review)
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List of abbreviations: 
 
5-MeO-DALT = N,N-diallyl-5-methoxytryptamine;  
(N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine) 
5-MeO-DiPT = 5-methoxy-diisopropyltryptamine 
AMT = Alpha-methyltryptamine 
DALT = N,N-Diallyltryptamine 
MAO-A = Monoamine oxidase A 
MAO-B = Monoamine oxidase B 
MDMA = 3,4-methylenedioxy-N-methylamphetamine 
Main text
Click here to view linked References
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The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a 
brief review 
 
1 Introduction  
 
1.1 Tryptamine is a naturally occurring monoamine alkaloid found in plants and fungi. 
Chemically related to tryptophan, an amino acid, it is founded on the indole ring 
structure. Mammalian brains contain trace amounts of the substance which may act 
as a neurotransmitter or modulator (Jones, 1982), is a serotonin releasing agent 
(Wölfel and Graefe, 1992), and serotonergic activity enhancer (Shimazu and Miklya, 
2004), being metabolised by MAO-A and MAO-B (Sullivan et al., 1986). Chemical 
variants of naturally occurring tryptamines are obtained by modifying a side-chain or 
functional group. 
 
1.2 5-MeO-DALT (N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine;  
N,N-diallyl-5-methoxytryptamine) is very closely related chemically to the compounds 
5-MeO-DiPT (5-methoxy-diisopropyltryptamine) and DALT (N,N-Diallyltryptamine) 
(Figure 1) and was first synthesised by Alexander Shulgin (Shulgin and Shulgin, 
2010). The manufacturing instructions contained in his book can easily be found on 
the Internet. 
 
< Figure 1 here> 
 
1.3 It appears that drug users did not widely use this new substance. The 
Psychonaut Project in 2002 revealed 5-MeO-DALT as one of a new group of 
tryptamines (Indolalkylamines) being experimented with by psychonauts, i.e. those 
who explore their own psyche especially by taking psychedelic or hallucinogenic 
substances  (Schifano et al., 2006). According to the European Database on New 
Drugs (EDND), it was first seen (as two grey tablets) in a Customs seizure at Helsinki 
airport, Finland, in December 2006, of a postal package with apparent Danish 
origins. The second report was the present death. Since then, German police seized 
687g powder in June 2010, Swedish police seized 0.8g of a dried herbal substance 
in January, 2011, UK police seized a green mixture containing several substances 
including 5-MeO-DALT at a „headshop‟ in March 2011, the Bulgarian authorities 
seized a capsule in May 2011, and Belgian police seized three minigrip bags at a 
Brussels Internet shop in August 2011: one contained 20.3g beige powder (with 
traces of methylone) and two contained 18.7g and 19.0g respectively of white 
powder (EDND, 2011). The EDND does not contain any information on the purity 
levels of these samples, all confirmed analytically. This substance seems to have 
been hardly used, known about generally, e.g. through general household or user 
surveys, or encountered by law enforcement and forensic science agencies or 
Emergency Rooms. This is especially true in the UK. For these reasons, there is very 
little scientific information about the drug, its pharmacology, metabolism, effects, 
toxicity, and epidemiology.  
 
2 Availability 
 
2.1 Originally advertised as a „plant fertiliser‟ or „plant food‟ but more recently as a 
„research chemical‟, 5-MeO-DALT comes as a salt or in free-base form. It was said 
by some consumers in 2004 to be „clumpish‟/‟sticky‟ but retail websites now make a 
point of describing it as free-flowing, with a slight smell, and its colour ranging from 
white to light-brown/tan. In February 2010 contributors to the BlueLight on-line 
discussion forum began suggesting that there were different „batches‟ of 5-MeO-
DALT in circulation (Bluelight, 2010). In September 2010, Erowid (the online library of 
information on psychoactive plants and chemicals) had analysed two samples 
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 3 
submitted to them following purchase from Internet sites. One sample proved to be 
very pure 5-MeO-DALT, but the second appeared to be flephedrone (4-
fluoromethcathinone) (Erowid and Spoon, 2010). A brief opportunistic Internet search 
at the end of September 2011 revealed that supplies of 5-MeO-DALT could be 
ordered in amounts ranging from 500mg to 20kg. Prices for European consumers 
ranged from €17 - €29 (US$23 - US$39) for 1g (sufficient for 40 to 50 doses) up to 
€4600 – €5400 (US$6200 - US$7300) for 1 kg. Prices were considerably higher – up 
to 5 times – for US consumers (as with other drugs). Websites advertising 5-MeO-
DALT usually display a disclaimer to the effect that it is “not for human consumption”, 
or that the “chemicals are only to be used by laboratories, scientific institutions and 
some science enthusiasts for private testing”. Clients also allegedly have to be aged 
18 years or older. 
 
3 Legal status 
 
3.1 There are no international controls, i.e. UN conventions, imposed on 5-MeO-
DALT. The substance is not scheduled in the USA. As an allyl-substituted tryptamine, 
5-MeO-DALT does not come within the generic definition of a (Class A) substituted 
tryptamine under the Misuse of Drugs Act 1971 in the UK; it would do if it was an 
alkyl group. However, it is now a controlled substance in Bulgaria, Finland and 
Romania (EDND, 2011).  In Japan, it is now regulated as a „designated substance‟ in 
terms of its importation, synthesis, and sale (Kamata et al., 2010). 
 
4 Route of administration 
 
4.1 There are several known routes of administration: insufflation (snorting, sniffing); 
intravenous injecting; oral (swallowing in a capsule, wrapped in a cigarette paper 
„bomb‟, or washed down with fruit juice); rectal; and vapourisation (inhalation) (Drugs 
Forum, 2010).  Shulgin and Shulgin (2010) recommended oral doses from 12 to 25 
mg for normal use, although initial doses of up to 50mg have been reported 
(Bluelight, 2010; Erowid, 2010). Oral ingestion appears to be the usual route of 
administration. 
 
5 Pharmacology 
 
5.1 There is a close structural likeness between serotonin and tryptamine. 
Tryptamines generally are hallucinogenic compounds, increasing the release of 
serotonin and inhibiting its reuptake. The structural similarities of synthetic 
tryptamines to serotonin may give rise to similar effects (Gibbons, 2012).  
 
5.2 There is little information on the pharmacodynamics and pharmacokinetics of 5-
MeO-DALT. In vitro research on rat brains has demonstrated that this substance 
appears to elicit G protein activation via serotonin 5-HT1 (5-hydroxytryptamine) 
receptors (Nonaka et al., 2007). It appears to have no detectable effect on dopamine, 
5-HT or norepinephrine re-uptake; and only slight monoamine-releasing activity 
(Nagai et al., 2007). Although the affinity of 5-MeO-DALT to specific 5-HT receptors 
has not been investigated, the related substance 5-MeO-DiPT has shown in vitro 
affinity for the 5-HT1A  receptor,  but less so for the 5-HT2A and 5-HT2C receptors 
(Fantegrossi et al., 2006). Also, 5-MeO-DALT has been shown to be a competitive 
inhibitor of the Serotonin reuptake transporter (SERT) (Sogawa et al., 2007; Nagai et 
al., 2007).   
 
5.3 Although the metabolism of 5-MeO-DALT has not been explored that of a closely 
related tryptamine analogue 5-MeO-DIPT has been recently examined, with three 
main metabolites having been identified as 5-hydroxy-N,N-diisopropyltryptamine (5-
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 4 
OH-DIPT); 6-hydroxy-5-methoxy-N,N-diisopropyltryptamine (6-OH-5-MeO-DIPT), 
and 5-methoxy-N-isopropyl-tryptamine (5-MeO-NIPT) (Kamata et al., 2010). Similar 
metabolic pathways have been found for other tryptamine-derived hallucinogens; it 
may be, therefore, that similar pathways exist for 5-MeO-DALT. 
 
6 Effects 
 
6.1 Most of the information published on the effects of 5-MeO-DALT is derived from 
first-hand personal accounts presented in discussion fora. User reports suggest that 
its effects are felt within 15 minutes of being taken orally, and its full effects within 30 
minutes. This, according to Shulgin and Shulgin (2010), suggests absorption into the 
blood stream directly from the stomach and rapid metabolism. User reports on 5-
MeO-DALT state rapid, strong entheogenic effect, euphoric, sensual, energised 
bodies, visual hallucinations (similar to those experienced with MDMA), loss of 
control of limbs making walking difficult, and „out of body‟ type experience (Erowid, 
2010). Some users on low doses have reported no after effects. The main effects of 
the substance last for 2 - 4 hours, but the visual effects persist for a while longer 
(Erowid, 2010). The intensity of such effects appears to be dose-related (Erowid, 
2010).  
 
6.2 Self-reported acute physical effects, unsubstantiated by medical observation, 
may include: vaso-constriction, increase in blood pressure, rapid heart-beat, 
headache, and sweating. Other side-effects reported include: the urge to eat 
(„munchies‟), dilated pupils, tension in the neck and jaw (bruxism), slight paranoia or 
anxiety, nausea (Erowid, 2010). Acute mental effects reported include: increased 
alertness and awareness; increased arousal; and agitation (Erowid, 2010).  
 
7 Toxicity 
 
7.1 According to Nichols (2004), the tryptamine class are normally unlikely to “cause 
life-threatening changes in cardiovascular, renal or hepatic function because of their 
lack of affinity for the relevant receptors and targets”. However, the consumption of 
alpha-methyltryptamine/α-methyltryptamine (AMT) and/or 5-MeO-AMT („foxy‟) has 
been associated with US fatalities (Boland et al., 2005). Whilst the clinical effects of 
tryptamine are similar when a methoxyl (or hydroxyl) group is added at position 5 of 
the tryptamine ring, there is also increased potency (Rogawski and Aghajanian, 
1981). 5-substituted tryptamines such as 5-methoxy-diisopropyltryptamine (5-MeO-
DiPT) have been implicated in death. An individual with known polyarteritis nodosa 
died of acute cardiac failure due to neurotoxicity caused by an overdose of this drug 
(Tanaka et al., 2006). There are also case reports of hallucinations and paranoia 
(Wilson et al., 2005). The hallucinogenic effects of such tryptamines may lead to 
disturbances in behaviour, resulting in life-threatening situations (Peden et al., 1981). 
 
7.2 Despite the time-period during which 5-MeO-DALT has been on the scene there 
is no information on its long-term effects. There have been no previously reported 
deaths from 5-MeO-DALT, although there has been at least one admission to 
hospital for observation following a particularly unpleasant „trip‟ (Drugs Forum, 2010), 
and an overdose within 3 months of Shulgin releasing the recipe on his website in 
May 2004. The US victim had ingested 225mg of the drug (Kamata et al, 2010). Its 
safety profile is unknown. No definitive concentrations of 5-MeO-DALT have been 
established for toxic effects or death.  
 
8 Fatality involving 5-MeO-DALT  
 
8.1 Notification 
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8.1.1 The National Programme on Substance Abuse Deaths (np-SAD) receives 
information on a voluntary basis from coroners in the United Kingdom concerning 
inquests completed on drug-related deaths (Ghodse et al, 2010). Here we present a 
report on a death in which the presence of 5-MeO-DALT was identified alongside 
ethanol detection. This case was notified in December 2010 as part of routine data 
submission. Additional information was provided by HM Coroner in the form of the 
autopsy and toxicology reports. 
 
8.2 Events leading to death 
 
8.2.1 In July 2010, a single white male in his mid-twenties, was seen to walk out into 
the slow lane of a motorway in front of a heavy goods vehicle at 02:00 hrs. He was 
hit by the vehicle, sustaining injuries to his skull. Ambulance personnel attended but 
despite extensive treatment the male‟s death was confirmed at 03:15 en route to 
hospital. The driver described how the deceased was continually grinning whilst 
walking on the motorway. At the inquest it was reported that he had earlier snorted 
350mg of 5-MeO-DALT (when the normal dose is 25mg) in a public house with a 
friend who had purchased 1g of it over the Internet for £20 (US$31, €23). The 
deceased described it as making him feel “pretty good”. He and his friend had been 
discussing trying „legal highs‟ for several weeks prior to the incident. The deceased 
had no medical history of note. 
 
8.3 Autopsy 
 
8.3.1 The autopsy, conducted about 33 hrs after death, found the deceased had 
sustained a significant head injury with a base of skull fracture and cerebral 
contusions, together with significant pulmonary contusions. There was no significant 
underlying natural pathology. The pathologist in this case recorded the cause of 
death as “fractured base of skull”. 
 
8.4 Toxicological investigation 
 
8.4.1 As part of a general (non-targeted) screening protocol, an initial toxicological 
investigation using high performance liquid chromatography with UV-diode array 
detection (HPLC-DAD) found that the post-mortem femoral blood contained an 
atracurium breakdown product (laudanosine) and propofol; their presence is 
consistent with medical intervention at the scene and on the way to hospital. The 
blood alcohol concentration was 22 mg/dL, indicating the consumption of alcohol at 
some point prior to death. A compound was detected in the blood with a distinctive 
tryptamine-like UV spectrum. Tryptamine itself is regularly observed as a putrefactive 
compound. No other drugs were detected, including purported “Legal Highs” such as 
piperazines and cathinones. 
 
8.4.2 Following the provision of further information about the deceased‟s 
consumption of 5-MeO-DALT, supplementary toxicological analysis was undertaken 
of the post mortem femoral blood samples. This was performed using liquid 
chromatography with mass spectrometry detection (LC-MS) as it can be difficult to 
distinguish between tryptamine and other naturally occurring tryptamine-related 
compounds and those with methoxytryptamine derivatives (including 5-MeO-DALT) 
with similar UV spectra. Primarily based on the pseudo molecular ion (MW = 
270.3694, [M+H] = 271.37) with supporting mass fragmentation, LC-MS analysis 
indicated the compound was 5-MeO-DALT. This was later confirmed following 
analysis of pure reference material. However, due to the time for the standard to 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
become available, it was not possible to measure the compound in the blood within 
the Coronial inquest period.  
 
8.5 Coroner‟s verdict 
 
8.5.1 The Coroner returned a narrative verdict on 28 October 2010: "He died from 
injuries sustained after being hit by a lorry whilst under the influence of 5-MeO-
DALT". He added, “It is a tragedy when anybody who takes drugs dies because of it, 
especially when it is a substance easily purchased from the Internet and purchased 
legally in this case” (Makey, 2010). 
 
9 Discussion  
 
9.1 The experiences and effects of 5-MeO-DALT are similar to those reported by 
users of other tryptamines, methylenedioxypyrovalerone (MDPV) and some 
methcathinone analogues (Schifano et al., 2006).  Importantly, it appears to act as a 
hallucinogen and can alter perception, including the assessment of risk. Use of this 
substance may therefore increase the possibility of poor assessment of situations, 
resulting in accidents (Gibbons, 2012); for example, as described in the case 
described here and that reported by Wilson et al. (2005)..  
 
9.2 Since 5-MeO-DALT has similar UV spectra as naturally occurring tryptamines, it 
is important that forensic toxicologists and Emergency Department physicians do not 
overlook the possibility of the ingestion of recreational tryptamines. Whenever 
possible, full details should be obtained of the circumstances leading to 
hospitalisation or death so that the appropriate toxicological investigations and 
medical interventions are performed. 
 
9.3 At the time of writing, no poisonings or fatalities involving 5-MeO-DALT have 
been reported in the scientific literature. Indeed, this paper is believed to be the first 
such article to describe a fatality in which the presence of 5-MeO-DALT was 
recorded. There is no reliable relevant pharmacokinetic information on 5-MeO-DALT 
in terms of lethal dosage, half-life, volume of distribution, etc. Fatalities involving 
tryptamine analogues appear to be very rare events and thus there is limited 
published evidence which can be used to inform cases such as the present one with 
respect to closely-related tryptamines; one fatality in Japan involved 5-MeO-DiPT 
ingestion. The decedent had been given a rectal administration of the substance to 
enhance his sexual experience. He became very agitated, was taken to hospital but 
died 3.5 hrs later. The cause of death was considered to be acute cardiac failure due 
to an overdose of the drug (Tanaka et al., 2006).  
 
9.4 It is difficult to keep abreast of the new products being created by „research 
chemists‟, which warrants establishment of a readily accessible forensic toxicology 
database of samples of new psychoactive substances.   
 
10 Conclusions 
 
10.1 This paper has outlined what is presently known about 5-MeO-DALT. It has also 
described what we believe to be the first death in the UK, and probably world-wide, 
involving the presence of the drug 5-MeO-DALT and which contributed to death. Due 
to its relatively recent emergence on the scene, its lack of widespread use, unknown 
toxicity and lack of detection through routine toxicological screens, use of this 
substance could be missed by clinicians. Similarly, fatalities involving this substance 
may be overlooked by those investigating sudden deaths with no apparent cause(s). 
Determination of the significance and role in death, if any, has to be provisional and 
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 7 
delivered with caution, qualifications and reservations. Without the additional 
information provided by the decedent‟s companion, this UK fatality could have been 
recorded as „accidental‟ due to injuries sustained in road traffic accident and alcohol 
intoxication.  
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Figure 1: Chemical structure of 5-MeO-DALT and related substances   
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